RecruitingMultiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
You may qualify if…
- ✓ History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E).
- ✓ Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
- ✓ Eastern Cooperative Oncology Group performance status of 0-1.
- ✓ Adherence to contraception requirements.
You may not qualify if…
- ✕ Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
- ✕ Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2).
- ✕ Other protocol-defined inclusion/exclusion criteria apply.
Where it's recruiting
Alabama
Birmingham
Arizona
Phoenix
California
Duarte
Florida
Jacksonville
Georgia
Atlanta
Massachusetts
Boston
Minnesota
Rochester
Nebraska
Omaha
New Jersey
Hackensack
New York
Buffalo · New York
Pennsylvania
Pittsburgh
Tennessee
Nashville
Source: ClinicalTrials.gov · NCT06121843 · last updated 2026-07-16